Temporal loss of efficacy of monoclonal CGRPantibody treatment following an infection with SARS-CoV-2: A case report by Hesham Hegazi in Journal of Clinical Case Reports Medical Images and Health Sciences
Temporal loss of efficacy of monoclonal CGRPantibody treatment following an infection with SARS-CoV-2: A case report by Hesham Hegazi in Journal of Clinical Case Reports Medical Images and Health Sciences Abstract Keywords : SARS-CoV-2, fremanezumab, CGRP, monoclonal antibody, COVID-19, migraine Increase of migraine frequency or pain intensity triggered by viral infections is common, in some patients a migraine status may be a consequence (1). In most patients migraine decreases after complete resolution of the infection and the course of disease reaches previous state. Due to the pandemic situation of SARS-CoV-2 patients switching from episodic to chronic migraine frequency are reported in close temporal relation to a COVID-19 disease (2). Until now there is one case published reporting decrease of efficacy of treatment with the monoclonal CGRP (calcitonin gene-related peptide)-receptor antibody erenumab in a migraine patient previously suffering from episodic migraine. Improvement ...